Posted on Wednesday, February 15, 2023 09:15 AM
To: Ottawa Physicians, Nurse Practitioners, Travel Clinics, Walk-in Clinics, Emergency Departments and CHCsDate: February 15, 2023From: Dr. Laura Bourns (Associate Medical Officer of Health, Acting)
Dear Colleagues:
This Public Health Alert summarizes recent updates to MPOX (formerly monkeypox) relating to epidemiology, risk factors, and reminders about recommendations for vaccination and testing.
MPOX Epidemiology & Risk Factors
Four (4) new individuals have tested positive for MPOX in Ontario...
Posted on Friday, January 27, 2023 10:00 AM
Provider
University of Ottawa’s Office of Continuing Professional Development
OverviewThis 1-day conference focusing on women’s health is designed to provide family physicians and healthcare professionals with the most current and relevant information about approaches on health issues concerning both young and mature women.
Date / Time / LocationFamily physicians and healthcare professionals.
Posted on Friday, January 27, 2023 10:00 AM
Provider
University of Ottawa’s Office of Continuing Professional Development
OverviewThis comprehensive 3-day course is designed to provide family physicians and other health-care providers with relevant and recent information about approaches to the diagnosis and management of conditions across the breadth of family medicine in both rural and urban settings. Each day will consist of a combination of lectures and workshop sessions designed specifically for family physicians and healthcare...
Posted on Friday, January 27, 2023 10:00 AM
The Royal has shared links to COVID Frontline Wellness, a new service to help health care workers cope with COVID-related stress and support their mental wellbeing. It offers confidential support through an online form to connect you with a trained mental health professional.
Posted on Friday, January 27, 2023 10:00 AM
In December 2022, Ontario Health issued a memo to health care providers with updated and expanded recommendations on the use of Paxlovid™ (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use) for the treatment of COVID-19.
Paxlovid™ should be strongly considered for individuals with a confirmed COVID-19 diagnosis, who present within 5 days of symptom onset and who have a higher risk of complications or severe outcomes from COVID-19 including :